Filtrer vos résultats
- 4
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 4
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use ProgramHepatology, 2018, 68 (1), pp.374A
Article dans une revue
hal-03590862v1
|
|||
Sofosbuvir plus velpatasvir plus voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use programJournal of Hepatology, 2019, 70 (1, 1), pp.E224. ⟨10.1016/S0618-8278(19)30417-7⟩
Article dans une revue
hal-03590860v1
|
|||
PERSISTENT MODERATE ALCOHOL CONSUMPTION IMPACTS SURVIVAL IN PATIENTS WITH COMPENSATED ALCOHOL-RELATED CIRRHOSIS: ANALYSIS OF THE CIRRAL COHORT.Hepatology, 2021, 74 (1), pp.87A-88A
Article dans une revue
hal-03590851v1
|
|||
|
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenibRevue Européenne des Éléments Finis, 2016, 15, ⟨10.1186/s12943-016-0526-2⟩
Article dans une revue
hal-03589432v1
|